Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies.

We also have a commercial business unit that markets ZanthoSyn^®, a novel astaxanthin dietary supplement with superior absorption and purity. ZanthoSyn^® is available through Cardax’s commercial website, www.zanthosyn.com.

Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. More than 50 human clinical trials supporting the safety and efficacy of astaxanthin have been conducted to date. As the broader scientific community has discovered the health benefits of astaxanthin, awareness and demand for astaxanthin has grown dramatically.